RT Journal Article
SR Electronic
T1 Evidence for non-Mendelian inheritance in spastic paraplegia 7
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.25.20176032
DO 10.1101/2020.09.25.20176032
A1 Mehrdad A Estiar
A1 Eric Yu
A1 Ikhlass Haj Salem
A1 Jay P. Ross
A1 Kheireddin Mufti
A1 Fulya Akçimen
A1 Etienne Leveille
A1 Dan Spiegelman
A1 Jennifer A. Ruskey
A1 Farnaz Asayesh
A1 Alain Dagher
A1 Grace Yoon
A1 Mark Tarnopolsky
A1 Kym M. Boycott
A1 Nicolas Dupre
A1 Patrick A. Dion
A1 Oksana Suchowersky
A1 Jean-Francois Trempe
A1 Guy A. Rouleau
A1 Ziv Gan-Or
YR 2020
UL http://medrxiv.org/content/early/2020/09/27/2020.09.25.20176032.abstract
AB Hereditary spastic paraplegia is a group of rare motor neuron diseases considered to be inherited in a classical monogenic Mendelian manner. Although the typical inheritance of spastic paraplegia type 7 is autosomal recessive, several reports have suggested that SPG7 variants may also cause autosomal dominant HSP. We aimed to conduct an exome-wide genetic analysis on a large Canadian cohort of hereditary spastic paraplegia patients and controls to examine the association of SPG7 and hereditary spastic paraplegia. In total, 585 hereditary spastic paraplegia patients from 372 families and 1,175 controls, including 580 unrelated individuals, were analyzed for the presence of SPG7 variants. Whole exome sequencing was performed on 400 hereditary spastic paraplegia patients (291 index cases) and all 1,175 controls. After excluding 38 biallelic hereditary spastic paraplegia type 7 patients, the frequency of heterozygous pathogenic/likely pathogenic SPG7 variant carriers (4.8%) among hereditary spastic paraplegia unrelated index cases who underwent WES, was significantly higher than among unrelated controls (1.7%; OR=2.88, 95%CI=1.24-6.66, p=0.009). The heterozygous SPG7 p.(Ala510Val) variant was found in 3.7% of index cases vs. 0.85% in unrelated controls (OR=4.42, 95%CI=1.49-13.07, p=0.005). We identified four heterozygous SPG7 variant carriers with an additional pathogenic variant in genes known to cause hereditary spastic paraplegia, compared to zero in controls (OR=19.58, 95%CI=1.05-365.13, p=0.0031; Fisher’s Exact test with Haldane-Anscombe correction), indicating potential digenic inheritance. We further identified four families with heterozygous variants in SPG7 and SPG7-interacting genes (CACNA1A, AFG3L2 and MORC2). Out of these, there is especially compelling evidence for epistasis between SPG7 and AFG3L2. The p.(Ile705Thr) variant in AFG3L2 is located at the interface between hexamer subunits, in a hotspot of mutations associated with spinocerebellar ataxia type 28 that affect its proteolytic function. Our results provide evidence for complex inheritance in SPG7-associated hereditary spastic paraplegia, which may include recessive and possibly dominant and digenic/epistasis forms of inheritance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580_260005, and by a CIHR Foundation grant granted to GAR. MAE is funded by the Fonds de Recherche du Quebec_Sante (FRQS). This research was undertaken thanks in part to funding from the Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative granted to MAE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants have signed an informed consent form prior to enrollment, and the The McGill University Health Center (MUHC) Research Ethics Board (REB) have approved the study protocols, REB number IRB00010120.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full protocol is available upon request.